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ABSTRACT
This review discusses how the T-cell compartment in
common variable immunodeﬁciency is marked by the
premature arrest in thymic output, leading to T-cell
exhaustion and immune dysregulation. Although B
cells have been the main focus of the disorder, ample
experimental data suggest that T-cell abnormalities
can be seen in a large proportion of Freiburg Group
1a patients and those suffering from inﬂammatory
complications. The reductions in T-cell receptor
excision circles, naïve T cells, invariant NKT cells and
regulatory T cells suggest a diminished thymic output,
while CD8 T cells are driven towards exhaustion
either via an antigen-dependent or an antigen-
independent manner. The theoretical risk of anti-T-cell
therapies is discussed, highlighting the need for an
international effort in generating longitudinal data in
addition to better-deﬁned underlying molecular
characterisation.
Common variable immunodeﬁciency (CVID) is a
heterogeneous and enigmatic primary immunodeﬁ-
ciency disorder marked by the failure of humoral
immunity and immune dysregulation. The discover-
ies of T-cell-related molecular defects in hyper IgM
syndrome and Inducible T-cell costimulatory
(ICOS) deﬁciency highlighted the negative conse-
quences to humoral immunity of the absence of
T-cell support,1 2 and growing experimental data
are now suggesting that the T-cell compartment is
also disrupted in patients with CVID.
CD4 T-cell lymphopenia was ﬁrst noted among
patients with CVID3–5 and can dramatically reverse
the normal CD4:8 ratio when combined with
expansion of senescent CD8 T cells, a feature not
usually found in other antibody deﬁciencies.6
Despite the array of observed in vitro T-cell abnor-
malities, the clinical hallmarks of a T-cell immuno-
deﬁciency such as recurrent fungal and viral
opportunistic infections are lacking in the majority
of patients.
The heterogeneity of CVID and the progressive
change in its deﬁnition over the years make com-
paring experimental data between studies difﬁcult,
but much can still be learnt. This article will
examine existing experimental data in the litera-
ture regarding the role of T-cell defects in CVID
and discuss how infection risk may increase pro-
gressively with decreasing thymic output, while
the memory compartment shows evidence of
abnormal activation. Additionally, we will assess
these ﬁndings in the context of the revised 2014
European Society for Immunodeﬁciencies (ESID)
diagnostic criteria and discuss their therapeutic
implications.
T-CELLS EXHAUSTION
In addition to the quantitative alterations in CD4
and CD8 T cells, abnormalities in cytokine produc-
tion and cell proliferation have been reported in
CVID. Experimental data for cytokine output have
been well summarised by Varzaneh et al,7 where
sluggish production of interleukin (IL) 2 along with
deﬁciencies in other cytokines such as IL-4, IL-5
and IL-10 were reported by a number of studies.7–9
On the contrary, high levels of inﬂammatory cyto-
kines such as IL-6, interferon (IFN)-γ and tumour
necrosis factor (TNF)-α were observed.7 During
the acute phase of a viral infection in immunocom-
petent individuals, elevations in the classical trio of
IL-2, IFNγ and TNFα are typically observed. By
contrast, studies in chronic hepatitis C and HIV
infections demonstrated that T-cell exhaustion, by
phenotypic and functional alterations, following a
long period of antigenic stimulation was typically
marked by the sequential disappearance of IL-2
and then TNFα.10 11 Therefore, the cytokine signa-
ture in CVID mimics an earlier phase of T-cell
exhaustion.
Studies of T-cell proliferation also support the idea
of a state of T-cell exhaustion. Earlier studies showed
that T-cell proliferation to phytohaemagglutinin and
OKT3 was normal in patients with CVID but
responses may be suboptimal against tetanus toxoid
or T-cell receptor (TCR) antibodies.12 Cyclic
AMP-dependent protein kinase A type 1 (PKAI), an
inhibitor of T-cell proliferation, can accumulate in
exhausted T cells following prolonged antigenic
stimulation.13 14 Using a PKAI selective antagonist,
Aukrust et al15 demonstrated that normal prolifer-
ation may be restored, suggesting that the poor T-cell
proliferation in CVID was secondary to senescence.
Programmed cell death protein 1 (PD-1), an
extended family member of CD28 and Cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), func-
tions as an important immune checkpoint for T cells
and negatively regulates immune responses. In a
murine lymphocytic choriomeningitis virus model,
the synergistic use of IL-2 therapy and PD-1 block-
ade was able to reverse the exhausted immunophe-
notype of CD8 T cells and to regain control over
the infection.16 Similar to the PKAI antagonist
experience, Perreau et al17 showed that in vitro CD4
proliferation in patients with CVID may also be
restored by blocking the programmed death ligand 1
and 2 axes (PD-L1/2). While anti-PD-1 antibodies
have not been directly tested in CVID, clinical
improvement was reported in patients who received
IL-2 therapy in the past.18 19 Along with suboptimal
proliferation responses, a small number of studies
also suggest an impaired apoptotic function contrib-
uting to the accumulation of effete T cells.20–22
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Overall, both in vivo and in vitro data suggest the presence of
potentially reversible T-cell exhaustion in some patients with
CVID.
EXAGGERATED CD8 T-CELL RESPONSES
While the cause of T-cell exhaustion in CVID is not clear, com-
parable immunophenotypic features can be found with chronic
viral reactivation, raising the possibility of an antigenic driver. T
cells of patients with CVID, in particular CD8 T cells, exhibit
high levels of activation and memory markers including CD29,
CD38, CD95, CD45RO and Human leukocyte antigen
(HLA)-DR, and low expression of CD27, CD62L and
CD45RA.23–26 Although the expansion of T-cell memory is
natural with advancing age, this process is greatly enhanced in
CVID. Similarly, a disproportionate increase in terminally differ-
entiated, senescent T cells (CCR7−CD45RA+) which are posi-
tive for CD57 and PD-1 was found across multiple studies,
further supporting the presence of a persistent, unregulated cel-
lular immune response in CVID.6 17 26 27 Unlike T-cell prolifer-
ation and cytokine output, immunophenotypic ﬁndings are
more consistent across studies and affect a larger proportion of
patients with inﬂammatory complications such as polyclonal
proliferation, chronic enteropathy, interstitial lung disease and
autoimmunity.
To further support the presence of an underlying antigenic
driver, CD8 T cells were shown to be oligoclonal by TCR
spectratyping.28–30 As normal repertoire diversity can be seen in
age-matched X-linked agammaglobulinaemia patients, this oligo-
clonality was not thought to be secondary to the deﬁciency in
antibodies.29 In addition, some patients with CVID were shown
to carry very dominant, stable CD8 clonotypes over time.29
Consistent with the notion of an underlying antigenic driver, a
unique set of hyperexpanded TCRβ complementarity determin-
ing region 3 (CDR3) sequences could be found among patients
with CVID. Although previous reports highlighted the preferen-
tial use of Vβ 4, 12 and 17 gene segments in these expanded
clonotypes,20 31 both Ramesh et al32 and our work could not
reproduce these results using modern next-generation sequen-
cing approaches and the level of oligoclonality was much more
subtle.
Using a pentamer speciﬁc for HLA-A2 cytomegalovirus
(CMV) peptide (NLV: NLVPMVATV), Marashi et al examined
the role of CMV as a putative antigenic driver in CVID. A
higher frequency (1–1.5%) of CMV NLV-speciﬁc CD8 T cells
co-expressing high levels of IFNγ and TNFα was found in
patients with CVID when compared with healthy controls
(0.25%), while the frequency of Epstein–Barr virus-speciﬁc
T cells was not increased.33 Similarly, Ki76 expression, a prolif-
eration marker, in NLV-speciﬁc CD8 T cells was greatly
increased in patients with CVID with inﬂammatory complica-
tions (2.4% vs 0.32%).34 Although causality could not be
demonstrated and bystander activation of CMV-speciﬁc T cells
could not be ruled out, an exaggerated CMV immune response
appears to be closely associated with inﬂammatory complica-
tions in CVID.
Autoimmunity is another potential candidate driver for an
exaggerated T-cell response. In patients with chronic diarrhoea,
T-cell aggregates and nodular lymphoid hyperplasia are often
found in intestinal biopsies, mimicking graft-versus-host
disease.35–38 However, detailed examination of tissue T cells is
technically challenging and it is currently not possible to differ-
entiate if these histological features are driven by infections, for
example norovirus,39 autoimmunity or other pathological
mechanisms. Furthermore, a recent study suggested that tissue
inﬂammation in CVID is largely driven by CD3− innate lymph-
oid cells as opposed to T cells.40
Overall, chronic activation of CD8 T cells in CVID either via
an antigen-dependent or antigen-independent manner is likely
to contribute to T-cell exhaustion. While CMV appears to be a
promising antigenic driver, the role of autoimmunity remains
unconﬁrmed and awaits further study.
REDUCTION IN THYMIC OUTPUT
Although current studies have not conﬁrmed a putative anti-
genic driver, the exaggerated T-cell response could also be due
to a lack of regulation. By peripheral blood immunophenotyp-
ing, Fevang et al were the ﬁrst to demonstrate a lower frequency
of CD4+CD25+FOXP3+ T cells, an immunophenotype consid-
ered characteristic of regulatory T cells (Treg), in patients with
CVID. RNA transcript levels for FOXP3 in CD4 T cells were
also lower in patients, particularly in those with splenomegaly.
To further support this, the frequency of Treg was inversely pro-
portional to neopterin, a serum inﬂammatory protein.41 Several
studies had since conﬁrmed the reduction in peripheral blood
Tregs (CD4+CD25+FOXP3+ or CD4+CD25+CD127−) with
the greatest deﬁciencies identiﬁed in patients with autoimmune
cytopenias or Freiburg Group 1a.42–45 Carter et al46 also sug-
gested an association between decreased Tregs and CD8 T-cell
exhaustion in CVID.
Poor expressions of CTLA-4 and Glucocorticoid-induced
TNFR-related protein (GITR) on Tregs were also noted, suggest-
ing a functional deﬁcit.46 47 Tregs isolated from patients with
CVID and autoimmunity had inferior suppressive function
when cocultured with autologous CD4+CD25− T cells,
although it is not clear if this phenomenon is primary or sec-
ondary, such as thymic sequestration by chronic infections.42
CTLA-4 haploinsufﬁciency had been identiﬁed in cohorts of
patients with CVID and impaired Treg functions.48 49 An
ongoing international collaboration is being carried out to esti-
mate the prevalence of this mutation among patients with
CVID.
Altogether, deﬁciency in Treg provides a logical explanation
for the presence of overexpanded and exhausted CD8 T cells, as
well as the development of autoimmunity CVID patients.
The examinations of other thymic derived T cells suggest that
the reduction in Tregs may be part of a much broader picture.
Invariant NK T cells (iNKT) are a subset of T cells that exhibit
both characteristics of NK cells and T cells. They have highly
restricted TCRs (Vα24/Vβ11) and are responsible for a range of
immune responses, in particular the control of chronic viral
infections.50 Using CD1d tetramers and Vα24/Vβ11 antibodies,
Fulcher et al51 ﬁrst demonstrated a signiﬁcant reduction in
iNKT among Freiberg Group 1a CVID patients. The numerical
reduction of iNKTwas later conﬁrmed by other groups.52 53 In
one study, almost half of the patients had no circulating iNKTs.
Stimulation with CD1d tetramer and α-galcer, a natural ligand
for iNKT, also failed to adequately expand the iNKT popula-
tion.54 The combined reduction in both Treg and iNKT high-
lighted a potential problem with thymic output, as both are
considered as primary products of the thymus.55–57 In keeping
with this, immunophenotypic data often reveal lower frequen-
cies of naïve (CD45RA+CCR7+) CD4 and CD8 T cells in
CVID. Other T-cell compartments such as central memory,
effector memory and terminally differentiated T cells were rela-
tively unaffected or proportionally increased in frequencies, sug-
gesting that T-lymphopenia in CVID is predominantly restricted
to the naïve pool in which a numerical deﬁcit was conﬁrmed by
bead-calibrated absolute counting. In addition, a reduction in
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recent thymic emigrants (CD45RA+CD31+) was also
shown.6 58 Finally, the T-cell receptor excision circle (TREC) is
a gene segment by-product of VDJ rearrangement not replicated
during cell division and is considered as the gold standard in
measuring thymic output and recent thymic emigrants.59 As
much as a 10× fold reduction in TREC was reported in both
CD4 and CD8 T cells of patients with CVID when compared
with age-matched healthy controls.60 61
Therefore, ample experimental data support the reduction in
thymic output in CVID. As proposed by Liston et al,62 reduc-
tion in thymic output in other partial T-cell immunodeﬁciencies
may promote autoimmunity by disrupting the balance between
effector and regulatory T cells. It is, thus, not surprising that the
majority of the ﬁndings described so far in this article gravitate
towards Freiberg Group 1a patients who have a higher rate of
autoimmune complications. The disappearance of iNKT would
further hinder B-cell activation and memory formation.63 It is,
however, important to note that many T-cell independent
mechanisms such as CLEC16A and Transmembrane activator
and calcium modulator and cyclophilin ligand interactor (TACI)
polymorphism may also mediate autoimmunity,64 65 and thymic
failure thus represents just one of several mechanisms for
patients with CVID to develop autoimmunity. In addition to the
increased risk of infection and autoimmunity, T-cell lymphope-
nia would theoretically impair tumour surveillance, predisposing
patients to both haematological and non-haematological malig-
nancies as suggested by Brent and colleagues.66
B-CELL AND T-CELL COLLABORATION
While poor thymic function could lead to the observed T-cell
abnormalities in CVID, it offers little explanation for the
humoral deﬁciency. With the exception of ICOS deﬁciency, the
connexion between B-cell and T-cell abnormalities in CVID
remains largely speculative.2 It is possible that the reduction in
naïve T cells limits available cognate T cells to support humoral
function. In keeping with that, the loss in naïve CD4 T cells was
associated with increased infections.20 IL-21-producing follicu-
lar T-helper cells are derived from naïve T cells and play a
crucial role in supporting germinal centre functions.67 However,
conﬂicting evidence exists in the literature regarding their role
in the disease process.6 68
On the other hand, the combined failure of T cells and B cells
warrants further examination of the common progenitors.
Interestingly, bone marrow progenitor cells from patients with
CVID were less able to form colonies when examined by the
methylcellulose assay, indicating a problem even prior to thymic
selection.6 58 Consistent with this hypothesis, Serana et al69
showed that both TREC and Kappa-deleting element recombin-
ation circle (KREC) were proportionally reduced in CVID.69
Compared with severe combined immunodeﬁciencies such as
deﬁciencies in JAK3, RAG1 and IL7RA, the reduction in TREC
and KREC in CVID was only modest and partial.70 Similar to
the excision circle analyses, telomere length of T cells and B
cells correlated with each other, further supporting a common
progenitor defect driving the simultaneous failure of B cells and
T cells.71 However, telomere shortening was not consistently
demonstrated in all studies and more data are required to
support or refute this hypothesis.72
DIAGNOSTIC AND THERAPEUTIC CONSIDERATION
Given the prevalence of T-cell abnormalities among patients with
CVID, the recent redeﬁnition of CVID by the ESID now empha-
sises on the use of T-cell immunophenotyping during the diag-
nostic workup.73 However, while there is a sound rationale to
exclude patients with recurrent opportunistic infections and
late-onset combined immunodeﬁciency,74 the arbitrary cut-offs
for CD4 lymphopenia and naïve T-cell lymphopenia will exclude
a proportion of patients (box 1). Patients with massive spleno-
megaly and pancytopenia are not particularly susceptible to
opportunistic infections and may face diagnostic exclusion. As a
signiﬁcant amount of the T-cell data were generated before the
introduction of the revised ESID criteria, it will be of interest to
revisit T-cell functions under the new deﬁnition in the future.
The success of checkpoint inhibitors such as anti-PD-1 anti-
bodies used in some cancers and experimentally in T-cell
exhaustion raises the question if they have a therapeutic role in
CVID, with or without recombinant IL-2.75 However, the clin-
ical application of such therapies is unexplored outside the
oncology setting and untested in immunodeﬁcient patients. In
addition, there is a real risk of causing or exacerbating the auto-
immunity that characterises the very patients who might beneﬁt
from such T-cell resuscitation.
Studies of T cells also highlight for the need for speciﬁc con-
sideration for immunosuppressants and biologics in CVID.
While corticosteroids and rituximab are now widely prescribed
for cytopenias and inﬂammatory conditions in CVID,76 77 our
experiences with anti-T-cell agents are less well established with
long-term follow-up data still lacking. Given the diminished
thymic output, therapies targeting T cells should be very care-
fully considered and tailored or they risk compromising the
Box 1 ESID 2014 revised diagnostic criteria for common
variable immunodeﬁciency73
At least one of the following:
▸ Increased susceptibility to infection
▸ Autoimmune manifestations
▸ Granulomatous disease
▸ Unexplained polyclonal lymphoproliferation
▸ Affected family member with antibody deﬁciency
AND marked decrease of IgG and marked decrease of IgA with
or without low IgM levels (measured at least twice; <2SD of the
normal levels for their age)
AND at least one of the following:
▸ Poor antibody response to vaccines (and/or absent
isohaemagglutinins);
▸ That is, absence of protective levels despite vaccination
where deﬁned
▸ Low switched memory B cells (<70% of age-related normal
value)
AND secondary causes of hypogammaglobulinaemia have been
excluded (see separate list below)
AND diagnosis is established after the 4th year of life (but
symptoms may be present before)
AND no evidence of profound T-cell deﬁciency, deﬁned as
2 out of the following:
▸ CD4 numbers/microlitre: 2–6 years <300, 6–12 years
<250, >12 years <200
▸ % naive CD4: 2–6 years <25%, 6–16 years <20%,
>16 years 10%
▸ T-cell proliferation absent
T-cell criteria are marked in bold.
AND no evidence of Ataxia telangiectasia (cafe-au lait spots,
ataxia, telangiectasia, raised Alpha fetoprotein (AFP)).
ESID, European Society for Immunodeﬁciencies.
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existing T-cell immunity without replenishment from the
thymus in patients with inﬂammatory complications or Freiburg
Group 1a. In addition to improved molecular characterisation,
future studies should focus on gathering longitudinal data in
this area and test if latent viral control could be affected by
immunosuppressive therapies.
Finally, the combined defect in T cells and B cells provokes a
consideration for haematopoietic stem cell transplantation
(HSCT) in CVID, the only cure for a combined immunodeﬁ-
ciency disorder. A recent multicentre retrospective study involv-
ing 25 patients of various clinical presentations, mostly for
refractory immune dysregulation and lymphoma, showed that
endogenous immunoglobulin production can be revived after a
match-related donor or match-unrelated donor bone marrow
transplant.78 However, the procedure carries a signiﬁcant mor-
bidity and mortality rate (48% overall survival), much exceed
that of modern paediatric immunodeﬁciency HSCT (81–
92%).79 Also, many patients still required immunoglobulin
replacement afterwards, limiting its potential application.
CONCLUSION
Orthogonal evidence from multiple studies indicates an arrest in
thymic output coupled with exhaustion in the memory T-cell
compartment in patients with CVID and inﬂammatory compli-
cations or Freiburg Group 1a. It is anticipated that the revised
ESID diagnostic criteria will result in an increased focus on
T-cell abnormalities in CVID and it will be of interest to
re-examine many of the observed abnormalities in well-
characterised cohorts under the revised criteria. Importantly,
this review calls for additional care in the use of immunosup-
pressants in CVID, with close monitoring of outcomes, perhaps
through an international database.
Take home messages
▸ Reduction in thymic output is a common feature of CVID.
▸ T cells are driven towards exhaustion either via an antigen-
dependent or an antigen-independent manner.
▸ Additional care in the use of immunosuppressants is needed
to preserve patients’ existing immunity.
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